Published online Apr 28, 2021. doi: 10.13105/wjma.v9.i2.193
Peer-review started: January 28, 2021
First decision: February 24, 2021
Revised: March 31, 2021
Accepted: April 23, 2021
Article in press: April 23, 2021
Published online: April 28, 2021
Core Tip: The use of laboratory hematology data as biomarkers of disease has not been examined for coronavirus disease 2019 (COVID-19) patients with liver injury, and the clinical significance of liver injury in COVID-19 is unclear. By means of a systematic review we showed that blood cell count, absolute neutrophil count, absolute lymphocyte count (ALC), and hemoglobin are of potential use in identifying liver failure in COVID-19. ALC and d-dimer have potential utility in distinguishing severe from non-severe disease in patients with liver injury. Our findings provide a rationale for further studies with sufficiently large numbers of patients and rigorous definition of liver injury to validate these findings.